[Innovative strategies to diagnose and monitor tuberculosis patients].
Mycobacterium tuberculosis is the single most deadly microorganism worldwide. A third of the world population is thought to have latent tuberculosis and approximately 2 million people die of the disease each year. Short and closely supervised treatment regimens are needed, but it is also essential to develop new strategies to ensure prompt diagnosis of the disease. In particular, cheap methods are needed to tackle tuberculosis from a population perspective. The present article reviews the advances in immunology and molecular strategies for epidemiological diagnosis and monitoring of tuberculosis patients.
Palma-Nicolás
José Prisco
JP
Departamento de Inmunología, Instituto de Investigaciones Biomédicas, UNAM, México DF, México.
Bocanegra-García
Virgilio
V
D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008055:Lipids / Q000276:immunology; D009169:Mycobacterium tuberculosis / Q000276:immunology / Q000302:isolation & purification; D016133:Polymerase Chain Reaction; D015203:Reproducibility of Results; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000276:immunology* / Q000382:microbiology
D017152:Antibodies, Antiphospholipid; D000942:Antigens, Bacterial; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008055:Lipids